TipRanks
Go Ultimate55% OFF

ORIENTBIO, Inc. (002630) Price & Analysis

002630 Stock Chart & Stats

₩1,190.00-₩39.00(-3.17%)
At close: 4:00 PM EDT
KRW 1,250KRW 1,500KRW 1,750KRW 2,0003 Aug18 Aug31 Aug22 Sep28 Sep12 Oct26 Oct
Day’s Range
KRW 1,170.00 - KRW 1,263.00
52-Week Range
KRW 1,170.00 - KRW 3,264.00
Previous Close
KRW 1,229.00
Volume
N/A
Average Volume (3M)
51.38K
Market Cap
KRW 35.26B
Enterprise Value
KRW 68.05B
Total Cash (Recent Filing)
KRW 38.08B
Total Debt (Recent Filing)
KRW 1.19B
Price to Earnings (P/E)
15.3
Beta
-0.02
Next Earnings
Nov 12, 2026
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet

Very low leverage and a substantial equity buffer reduce financial strain and improve resilience through operating volatility. This gives ORIENTBIO greater flexibility to sustain laboratory and diagnostic operations, fund necessary investment, and absorb weaker periods without relying heavily on external financing.

TTM Profitability Rebound

The return to positive operating profit and an approximately 8% net margin indicates that the business can currently convert its laboratory and diagnostic activities into earnings. If maintained, this improved earnings base can support reinvestment and strengthen internal funding over the next several quarters.

Strong Recent Cash Generation

Healthy recent operating and free cash flow provides practical support for the reported earnings rebound, showing that profits are translating into substantial cash. This improves the company’s ability to finance operations, meet obligations, and pursue growth without depending principally on new borrowing.

Bears Say

Declining Recent Revenue

A roughly 3.7% TTM revenue decline signals that current demand or customer activity has not yet produced durable top-line expansion. Without renewed sales growth, the company may have less operating leverage and fewer resources to offset costs or build a stronger earnings trajectory.

Highly Volatile Earnings History

The wide swings between annual profits and losses make the latest profitable TTM period harder to treat as a stable run rate. Persistent earnings volatility reduces forecasting confidence, can complicate capital allocation, and raises the risk that profitability will weaken again over the next several reporting periods.

Inconsistent Cash Conversion

Although the latest TTM cash generation is strong, prior negative free cash flow and weak operating cash flow coverage show that conversion has not been dependable. Such inconsistency may reflect episodic cash requirements and makes internally generated funding less predictable during weaker operating periods.

002630 FAQ

What was ORIENTBIO, Inc.’s price range in the past 12 months?
ORIENTBIO, Inc. lowest stock price was ₩1170.00 and its highest was ₩3264.00 in the past 12 months.
What is ORIENTBIO, Inc.’s market cap?
ORIENTBIO, Inc.’s market cap is ₩35.26B.
When is ORIENTBIO, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ORIENTBIO, Inc.’s earnings last quarter?
ORIENTBIO, Inc. released its earnings results on Aug 14, 2026. The company reported ₩81.753 earnings per share for the quarter.
Is ORIENTBIO, Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does ORIENTBIO, Inc. pay dividends?
ORIENTBIO, Inc. does not currently pay dividends.
What is ORIENTBIO, Inc.’s EPS estimate?
ORIENTBIO, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ORIENTBIO, Inc. have?
ORIENTBIO, Inc. has 29,645,752 shares outstanding.
What happened to ORIENTBIO, Inc.’s price movement after its last earnings report?
ORIENTBIO, Inc. reported an EPS of ₩81.753 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ORIENTBIO, Inc.?
Currently, no hedge funds are holding shares in KR:002630
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology